JARDIANCE® Post Marketing Surveillance in Korean Patients With Chronic Kidney Disease (CKD)

Sponsor
Boehringer Ingelheim
Study ID
NCT06287073
Status
Completed

Conditions

  • Kidney Disease, Chronic

Eligibility Criteria

Sex
ALL
Age
19 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • JARDIANCE® — DRUG
    JARDIANCE®

Study Details

The primary objective is to monitor the safety profile of JARDIANCE® in Korean patient with chronic kidney disease (CKD) in routine clinical practice. The secondary objective is to monitor the efficacy of JARDIANCE® by evaluating changes in urine albumin-creatinine ratio (UACR) after 12 and/or 24 weeks of treatment.

Key Dates

First listed
Feb 29, 2024
Start date
Mar 29, 2024
Status verified
May 2026
Primary completion
Apr 30, 2025
Completion
Apr 30, 2025

Study Design

Enrollment
299 participants (actual)

Arms

  • Arm: JARDIANCE® treated patients
    Patients with chronic kidney disease (CKD) who started JARDIANCE® for the first time in accordance with the approved label in Korea, treated according to routine clinical practice.

Primary Outcome Measure

Number of Participants With Adverse Events (AEs) [ Time Frame: Up to 337 days. ]

Related coverage on Hipa.ai

Related Studies